← Russell 3000 cross-section

FHTX Foghorn Therapeutics Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$384m
Revenue TTM
$37m
Net income TTM
$-65m
Free cash flow
$-84m
Composite score
Sector rank
#2529

Valuation

P / E
EV / EBITDA
EV / sales
8.6
FCF yield
-21.94%
Earnings yield vs 10-yr
-21.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-175.8%
EBITDA margin
-192.2%
ROE
79.7%
ROIC
Revenue growth
52.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Included in the three and six months ended June 30, 2026 revenue amounts was a $14.2 million cumulative catch-up adjustment to reflect updated future costs primarily due to the scheduled expiration of the research term in December 2026.Foghorn Therapeutics Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →